Long-term metastatic breast cancer patient’s quality of life: patient’s opinion
Abstract
Metastasic breast cancer patients live longer thanks to the lasts improvements in their treatment. Nonetheless, there exist few studies focused on the quality of live (QoL) of those patients. The aim of our study is to improve the knowledge of metastatic breast cancer patient’s quality of life, for this purpose we have elaborated an open questionnaire as a complement to the QoL tests available. Material and methods: From June 2011 to February 2012 we conducted 24 interviews with a questionnaire based on medical and psychosocial items. Results: 58% of patients considered that treatment improved their QoL, an 83.3% expressed that the benefit of the treatment compensated for the secondary effects, complementary tests give them relieve, control over the illness and information. Only two thirds of those patients expressed to have social support, and one third said to share their grief with nobody. The main concerns expressed by the patients were in order of value: their family, loss of self-caring, fear about the future and to the illness progression. Half of the patients think that the disease has brought some value to their lives such as improving their scale of values and to improve empathy to somebody else’s problems. Conclusion: Metastatic breast cancer patient’s attitude is admirable in the way they are adapted to such a wearing situation. Nonetheless it’s imperative to offer them the help and the medical information they need to compensate for their solitude in front of the illness.Downloads
Article download
License
In order to support the global exchange of knowledge, the journal Psicooncología is allowing unrestricted access to its content as from its publication in this electronic edition, and as such it is an open-access journal. The originals published in this journal are the property of the Complutense University of Madrid and any reproduction thereof in full or in part must cite the source. All content is distributed under a Creative Commons Attribution 4.0 use and distribution licence (CC BY 4.0). This circumstance must be expressly stated in these terms where necessary. You can view the summary and the complete legal text of the licence.